Littérature scientifique sur le sujet « Human Leukocyte Antigen-G »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Human Leukocyte Antigen-G ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Human Leukocyte Antigen-G"
Curigliano, Giuseppe, Carmen Criscitiello, Lucia Gelao et Aron Goldhirsch. « Molecular Pathways : Human Leukocyte Antigen G (HLA-G) ». Clinical Cancer Research 19, no 20 (29 juillet 2013) : 5564–71. http://dx.doi.org/10.1158/1078-0432.ccr-12-3697.
Texte intégralSun, Juan, Yan-Xiang Chang et Chun-Yan Niu. « Evaluation of ascitic soluble human leukocyte antigen-G for distinguishing malignant ascites from benign ascites ». Tumor Biology 39, no 11 (novembre 2017) : 101042831772684. http://dx.doi.org/10.1177/1010428317726840.
Texte intégralMattuella, Letícia Grando, Lisiane Bernardi, Francis Maria Báo Zambra, Milene Borges Campagnaro, Rui Vicente Oppermann, Léder Leal Xavier, José Artur Bogo Chies et Letícia Algarves Miranda. « Human leukocyte antigen-G polymorphisms in periodontitis ». Acta Odontologica Scandinavica 78, no 2 (13 septembre 2019) : 141–45. http://dx.doi.org/10.1080/00016357.2019.1662942.
Texte intégralLiu, Yanqing, Meimei Lai, Yunyan Lou, Qiuyue Han, Qing Yang, Minguang Chen, Jingbo Li, Huiyan Wang, Weihua Yan et Xiaoqun Zheng. « Elevation of plasma-soluble HLA-G in childhood nephrotic syndrome is associated with IgE ». Annals of Clinical Biochemistry : International Journal of Laboratory Medicine 54, no 1 (28 septembre 2016) : 69–75. http://dx.doi.org/10.1177/0004563216637625.
Texte intégralMittal, Balraj. « Yoga, rheumatoid arthritis & ; human leukocyte antigen-G ». Indian Journal of Medical Research 155, no 2 (2022) : 225. http://dx.doi.org/10.4103/ijmr.ijmr_785_22.
Texte intégralMatte, Claudine, Lynn S. Zijenah, Julie Lacaille, Brian Ward et Michel Roger. « Mother-to-child human leukocyte antigen G concordance ». AIDS 16, no 18 (décembre 2002) : 2491–94. http://dx.doi.org/10.1097/00002030-200212060-00021.
Texte intégralFuiii, T. « Structure and function of human leukocyte antigen-G ». Placenta 19, no 7 (septembre 1998) : A15. http://dx.doi.org/10.1016/s0143-4004(98)91101-8.
Texte intégralWarner, Carol M., Paula W. Lampton, Judith A. Newmark et Jacques Cohen. « Soluble human leukocyte antigen-G and pregnancy success ». Reproductive BioMedicine Online 17, no 4 (janvier 2008) : 470–85. http://dx.doi.org/10.1016/s1472-6483(10)60233-7.
Texte intégralClark, David A. « Human Leukocyte Antigen-G : New Roles for Old ? » American Journal of Reproductive Immunology 41, no 2 (février 1999) : 117–20. http://dx.doi.org/10.1111/j.1600-0897.1999.tb00085.x.
Texte intégralZarkhin, Valeriya, Maria Bezchinsky, Li Li et Minnie M. Sarwal. « Soluble Human Leukocyte Antigen-G in Pediatric Renal Transplantation ». Transplantation 92, no 1 (juillet 2011) : e1-e2. http://dx.doi.org/10.1097/tp.0b013e31821d91a1.
Texte intégralThèses sur le sujet "Human Leukocyte Antigen-G"
Silva, Tarsia Giabardo Alves [UNESP]. « Efeito quimiopreventivo e modulador de HLA-G (Human Leukocyte Antigen - G) de Morelloflavona ». Universidade Estadual Paulista (UNESP), 2012. http://hdl.handle.net/11449/124078.
Texte intégralFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
As atividades biológicas e farmacológicas dos biflavonoides são diversas incluindo suas propriedades imunossupressivas, anticancerígenas, antioxidantes, antiangiogênicas, antibacterianas, antivirais e antifúngicas. No presente estudo, avaliou-se a potencial capacidade do biflavonoide morelloflavona, isolada de Garcinia xanthochymus, em modular a expressão de HLA-G (Human Leukocyte Antigen- G), bem como seu potencial efeito quimiopreventivo. Inicialmente, foi avaliado o índice de morte celular causado pela morelloflavona por meio do ensaio de Anexina V - Iodeto de proídio em PBMC (Células mononucleares do sangue periférico), o qual apresentou índices de morte celular significantes. Através da citometria de fluxo observou-se um aumento da expressão de HLA-G vinculado à membrana celular em linhagens de melanoma (FON) (p < 0,001). Pôde-se observar a indução de HLA-G solúvel em linhagens de melanoma transfectada (M8-HLA-G1) (p < 0,001), sem alteração para os demais tipos celulares estudados, pelo ensaio imunoenzimático- ELISA. A expressão de RNAm de HLA-G também foi induzida pela morelloflavona, observada pela RT- PCR, em células de melanoma M8 que não expressam HLA-G constitutivamente. Ainda, foi avaliada a atividade quimiopreventiva da morelloflavona. Observou-se a duplicação da atividade da enzima quinona redutase na linhagem de hepatocarcinoma celular (Hepa1c1c7) por meio do ensaio quinona redutase. Pelo ensaio do cometa foi possível verificar a capacidade genotóxica e antigenotóxica. Em relação à antigenotoxicidade, a morelloflavona causou dano de DNA no pré-tratamento. No pós-tratamento foi observado que a morelloflavona pode ter a capacidade de reverter danos de DNA causados pelo peróxido de hidrogênio. Sendo assim, os dados demonstrados revelam que a morelloflavona induz a expressão de HLA-G e possui efeito quimiopreventivo.
The biological and pharmacological activities of biflavonoids are diverse, including their immunosuppressive, anticancer, antioxidant, antiangiogenic, antibacterial, antiviral and antifungal properties. In the present study we assessed the potential ability of morelloflavone, a biflavonoid isolated from Garcinia xanthochymus in modulating the expression of HLA-G (Human Leukocyte Antigen-G), as well as their potential chemopreventive effect. First, we measured the rate of cell death by morelloflavone using Annexin V - Propidium iodide assay in PBMC (peripheral blood mononuclear cells), which showed significant levels of cell death. By flow cytometry was observed the increased expression of HLA-G membrane bound in melanoma cells line (FON) (p < 0.001). Also, was observed the induction of HLA-G soluble in transfected melanoma cells line (M8-HLA-G1) (p < 0.001), with no change to other cell types studied by Enzyme-linked immunosorbent assay - ELISA. The expression of HLA-G mRNA was also induced by morelloflavone, observed by RT-PCR, in melanoma cells (M8) that do not express HLA-G constitutively. Still, we evaluated the chemopreventive activity of morelloflavone. We observed a doubling of quinone reductase enzyme activity in hepatocellular carcinoma cells line (Hepa1c1c7) by quinone reductase assay. By comet assay we were able to verify the genotoxic and antigenotoxic capacity. Regarding antigenotoxicity, morelloflavone caused DNA damage pre treatment. In the posttreatment was observed that morelloflavone may be capable of reversing DNA damage caused by hydrogen peroxide. Thus, the data show that morelloflavone induces the expression of HLA-G and has chemopreventive effect.
FAPESP: 09/52716-4
CNPq: 140022/2010-4
CAPES: 0103-110
Silva, Tarsia Giabardo Alves. « Efeito quimiopreventivo e modulador de HLA-G (Human Leukocyte Antigen - G) de Morelloflavona / ». Araraquara, 2012. http://hdl.handle.net/11449/124078.
Texte intégralBanca: Raquel Alves dos Santos
Banca: Celso Teixeira Mendes Júnior
Banca: André Gonzaga dos Santos
Banca: Luis Octávio Regasini
Resumo: As atividades biológicas e farmacológicas dos biflavonoides são diversas incluindo suas propriedades imunossupressivas, anticancerígenas, antioxidantes, antiangiogênicas, antibacterianas, antivirais e antifúngicas. No presente estudo, avaliou-se a potencial capacidade do biflavonoide morelloflavona, isolada de Garcinia xanthochymus, em modular a expressão de HLA-G (Human Leukocyte Antigen- G), bem como seu potencial efeito quimiopreventivo. Inicialmente, foi avaliado o índice de morte celular causado pela morelloflavona por meio do ensaio de Anexina V - Iodeto de proídio em PBMC (Células mononucleares do sangue periférico), o qual apresentou índices de morte celular significantes. Através da citometria de fluxo observou-se um aumento da expressão de HLA-G vinculado à membrana celular em linhagens de melanoma (FON) (p < 0,001). Pôde-se observar a indução de HLA-G solúvel em linhagens de melanoma transfectada (M8-HLA-G1) (p < 0,001), sem alteração para os demais tipos celulares estudados, pelo ensaio imunoenzimático- ELISA. A expressão de RNAm de HLA-G também foi induzida pela morelloflavona, observada pela RT- PCR, em células de melanoma M8 que não expressam HLA-G constitutivamente. Ainda, foi avaliada a atividade quimiopreventiva da morelloflavona. Observou-se a duplicação da atividade da enzima quinona redutase na linhagem de hepatocarcinoma celular (Hepa1c1c7) por meio do ensaio quinona redutase. Pelo ensaio do cometa foi possível verificar a capacidade genotóxica e antigenotóxica. Em relação à antigenotoxicidade, a morelloflavona causou dano de DNA no pré-tratamento. No pós-tratamento foi observado que a morelloflavona pode ter a capacidade de reverter danos de DNA causados pelo peróxido de hidrogênio. Sendo assim, os dados demonstrados revelam que a morelloflavona induz a expressão de HLA-G e possui efeito quimiopreventivo.
Abstract: The biological and pharmacological activities of biflavonoids are diverse, including their immunosuppressive, anticancer, antioxidant, antiangiogenic, antibacterial, antiviral and antifungal properties. In the present study we assessed the potential ability of morelloflavone, a biflavonoid isolated from Garcinia xanthochymus in modulating the expression of HLA-G (Human Leukocyte Antigen-G), as well as their potential chemopreventive effect. First, we measured the rate of cell death by morelloflavone using Annexin V - Propidium iodide assay in PBMC (peripheral blood mononuclear cells), which showed significant levels of cell death. By flow cytometry was observed the increased expression of HLA-G membrane bound in melanoma cells line (FON) (p < 0.001). Also, was observed the induction of HLA-G soluble in transfected melanoma cells line (M8-HLA-G1) (p < 0.001), with no change to other cell types studied by Enzyme-linked immunosorbent assay - ELISA. The expression of HLA-G mRNA was also induced by morelloflavone, observed by RT-PCR, in melanoma cells (M8) that do not express HLA-G constitutively. Still, we evaluated the chemopreventive activity of morelloflavone. We observed a doubling of quinone reductase enzyme activity in hepatocellular carcinoma cells line (Hepa1c1c7) by quinone reductase assay. By comet assay we were able to verify the genotoxic and antigenotoxic capacity. Regarding antigenotoxicity, morelloflavone caused DNA damage pre treatment. In the posttreatment was observed that morelloflavone may be capable of reversing DNA damage caused by hydrogen peroxide. Thus, the data show that morelloflavone induces the expression of HLA-G and has chemopreventive effect.
Doutor
Azzazene, Dalel. « Cancer de l’ovaire et immunité anti-tumorale : rôle du Human Leukocyte Antigen-G (HLA-G) ». Thesis, Paris 11, 2012. http://www.theses.fr/2012PA11T086.
Texte intégralWith more than 15,000 deaths anticipated in 2012, ovarian cancer is the most deadly gynecologic malignancy. While approximately 80% of patients will respond to frontline chemotherapy, more than 60% of patients will experience disease recurrence and only 44% will be alive at 5 years. The role of the microenvironment in the process of carcinogenesis and tumor progression has been demonstrated in various studies. This original concept of initiation and tumor progression solicits a very varied conceptual and experimental approach. In this study, we demonstrate the important role of the immunosuppressive molecule HLA-G (Human Leukocyte Antigen-G), and its expression and regulation by cancer cells and tumor microenvironment cells. We studied the various factors involved in the mechanisms immune of tumor escape from the immune system and finally we analyse in vivo some chemotherapy protocols based on the immunomodulatory drugs
Shakhawat, Ayesha. « Function and regulation of human leukocyte antigen G in trophoblast derived cells : A model for the study of human feto-maternal tolerance ». Thesis, University of Essex, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.520116.
Texte intégralWong, Hoi-hei Vera, et 王愷曦. « Isolation of human leukocyte antigen G/cytokeratin 7 positive fetal cells from transcervical samples for potential use in prenatal genetic diagnosis ». Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2015. http://hdl.handle.net/10722/208587.
Texte intégralpublished_or_final_version
Obstetrics and Gynaecology
Master
Master of Philosophy
Ullah, Matti. « Immune Checkpoints in Peritoneal Carcinomatosis : HLA-G, PD-L1 & ; the Impact of Cancer Therapies ». Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS288.
Texte intégralPeritoneal carcinomatosis (PC) is a term used for widespread metastatic dissemination of cancer to the peritoneal cavity. It is characterized by the accumulation of fluid called “ascites” and is considered a terminal stage of cancer, as it is hard to treat. The overall survival rate for untreated patients is six-months. However, owing to modern techniques like HIPEC, the survival rate can be increased up to five years. The ascites accumulated in PC, consists of tumor cells, cytokines and immune cells. Cancer cells express specific proteins to suppress immune cells activity and their attack, known as immune checkpoints. PD-1/PD-L1 and CTLA-4 are well established immune checkpoint pathways adapted by cancer in evading immunity. Recently, HLA-G has been recognized as an immune checkpoint and has been found to decrease overall survival in several types of solid cancers. We evaluated the expression of HLA-G in ascites from ovarian carcinomatosis. We found that HLA-G is expressed by cancer cells in ascites from all of the patients(n=16) with ovarian carcinomatosis. Moreover, increased levels of sHLA-G1 and HLA-G5 were found in ascites. This presence of sHLA-G isoforms was found to be positively correlated with Tregs and negatively correlated with cytotoxic T-cells (CD8) and NK-cells suggesting the role of HLA-G in immune suppression. Further, we found that ascites can induce the expression of HLA-G in “Hospicells” via inflammatory cytokines. Among the inflammatory cytokines, TGF-β and IL-1β are of crucial importance in HLA-G induction with IL-1β being more potent compared to TGF-β. Further, we found that IL-1β induces HLA-G expression through NF-κB pathway.In a separate cohort of peritoneal carcinomatosis(n=27), consisting of patients with cancer from a different origin, we found that cancer cell cluster in ascites (n=23) had a heterogeneous gene expression of PD-L1, CTLA-4 and HLA-G. Further, we found that all of the patients presented soluble levels of HLA-G in their ascites. However, one patient was negative for soluble PD-L1 and only 5 patients presented soluble CTLA-4 levels in their ascites. This heterogeneity explains why some of the patients respond to immune therapy while others don’t. This also suggests the need for prescreening patients before immune therapy. Moreover, we found a very strong positive correlation (rs=0.793) between gene level of PD-L1 and CTLA-4, while no correlation was found for HLA-G with PD-L1 and CTLA-4 suggesting that HLA-G acts independently of both the immune checkpoints. Also, we evaluated the expression of these immune checkpoints by cells in peritoneal tissue (n=20). We found low expression of HLA-G and PD-L1, but the majority of the samples were found strongly positive for sHLA-G presence. This sHLA-G can provide an immune-suppressive environment for the attachment of the cancer cell clusters to the peritoneal membrane to form cancer nodule. Additionally, we developed an in-vitro cytotoxicity assay to show that the ascites can provide the immune-suppressive action by interfering with immune cell interaction and delaying the lysis of cancer cells by the immune cells.In parallel, we found that the differentiation of the cancer cells results in increased expression of immune checkpoints like HLA-G or PD-L1. This may render these cells more immune resistant and can protect against immune attack. However, in-vivo mice model is needed to study the oncogenic potential of these differentiated cells. Further, we report that the expression of HLA-G and PD-L1 is dependent on the cell cycle phase. The cancer cells, if blocked in mitotic phase express high levels of HLA-G and PD-L1, while lowest expression was observed in G1-phase. Therefore, we suggest avoiding the use of mitotic inhibitors as it may increase the immune suppression of cancer. Moreover, as Ki-67 is directly related to the mitotic index, we suggest developing a Ki-67 scale to evaluate the immune-suppressive profile of cancer patients
Sampangi, Sandeep. « Autologous human kidney proximal tubule epithelial cells (PTEC) modulate dendritic cell (DC), T cell and B cell responses ». Thesis, Queensland University of Technology, 2015. https://eprints.qut.edu.au/82033/1/Sandeep_Sampangi_Thesis.pdf.
Texte intégralCatamo, Eulalia. « Genetic variation in hla-g : its influence in autoinflammatory autoimmune and viral diseases ». Doctoral thesis, Università degli studi di Trieste, 2014. http://hdl.handle.net/10077/9982.
Texte intégralL'antigene leucocitario umano (HLA)-G presenta, in condizioni fisiologiche, una ristretta espressione tessuto-specifica ed ha funzione immuno-tollerogenica. Però, la presenza della molecola HLA-G è stata associata a diverse patologie autoimmuni e virali. In questo progetto di dottorato di ricerca abbiamo analizzato la possibile associazione tra la varianti genetiche nel gene HLA-G, che si suppone regolino l'espressione di HLA-G, e la suscettibilità allo sviluppo e al decorso della malattia celiaca, del lupus eritematoso sistemico, dell'artrite reumatoide e dell'infezione dal virus dell'epatite C. Inoltre, abbiamo analizzato se variazioni all'interno del promotore di HLA-G possano alterare la sua trascrizione genica, a questo scopo è stato condotto il saggio della luciferasi. Per gli studi di associazione sono stati analizzati 800 bp del promotore, l’intero 3’UTR e la delezione di una citosina all’esone 3 (ΔC, allele HLA-G*0105N) in 402 pazienti celiaci e 509 controlli italiani; 114 pazienti con lupus eritematoso sistemico e 128 controlli sani provenienti dal Nord -Est del Brasile, 127 pazienti con artrite reumatoide e 128 controlli dal Nord-Est del Brasile, e 286 pazienti caucasici HCV positivi e 285 controlli provenienti dalla stessa area geografica. Il saggio della luciferasi è stato condotto su 9 diversi aplotipi al promotore del gene HLA-G: CCTAGGACCG, CGTAGGACCG, CTTAGGACCG, TCGGTACGAA, TGGGTACGAA, TTGGTACGAA, CCTAGGAGCG, CGTAGGAGCG, e CTTAGGAGCG. Numerosi SNPs e aplotipi del gene HLA-G sono stati associati con le malattie analizzate. Inoltre, il saggio della luciferasi ha permesso di constatare che la presenza di polimorfismi, nel promotore del gene HLA-G, altera la trascrizione genica; nello specifico, in condizioni di stress, l’allele -725 C era significativamente associato ad un aumento della trascrizione del gene rispetto agli alleli -725 G e T. I nostri i risultati indicano un'associazione tra i polimorfismi del gene HLA-G e la suscettibilità allo sviluppo delle malattie studiate, suggerendo che molecola HLA-G è coinvolta nella patogenesi di queste malattie. Inoltre, possiamo ipotizzare che il gene HLA-G sia un gene stress-inducibile e che la presenza di SNPs al promotore alterati i livelli di trascrizione del gene
The Human Leukocyte Antigen (HLA)-G present a physiological restricted tissue-specific expression and an immuno-tolerogenic functions. The HLA-G expression has been associated with various autoimmune and viral diseases. In this PhD project we analyzed the possible association between genetic variant in the HLA-G gene, supposed to regulate HLA-G expression, and the susceptibility to develop celiac disease, systemic lupus erythematosus, rheumatoid arthritis and hepatitis C virus infection. Furthermore, we analyzed if variations within the HLA-G promoter could alter its transcription, and for this reason luciferase reporter gene assays was conducted. The HLA-G 5’ upstream regulatory region (URR), 3’ untranslated region (UTR) and a cytosine deletion at exon 3 (ΔC, HLA-G*0105N allele) were analyzed in 402 celiac patients and 509 controls from Italy; 114 systemic lupus erythematosus patients and 128 healthy controls from North East Brazil; 127 rheumatoid arthritis patients and 128 controls from North East Brazil; and 286 Hepatitis C virus Caucasian patients and 285 controls from the same geographical area. The luciferase reporter gene assay was used for the HLA-G promoter CCTAGGACCG, CGTAGGACCG, CTTAGGACCG, TCGGTACGAA, TGGGTACGAA, TTGGTACGAA, CCTAGGAGCG, CGTAGGAGCG, and CTTAGGAGCG haplotypes. Several HLA-G SNPs and haplotypes were associated with the diseases analyzed. By luciferase reporter gene assay, we found that the presence of polymorphisms in the HLA-G promoter altered gene transcription, specifically -725 C allele was significantly associated with an increased of the HLA-G transcription with respect to -725 G and T alleles in stress condition. Our findings indicate an association between HLA-G gene polymorphisms and susceptibility to diseases development, suggesting that HLA-G molecule is involved in the pathogenesis of the diseases. Also, we can hypothesize that HLA-G gene is a stress-inducible gene and that the presence of SNPs to the promoter alter levels of transcription of the gene
XXVI Ciclo
1980
Santos, Kaisson Ernane dos. « Avaliação da história evolutiva do gene HLA-G por meio de polimorfismos de base única e da inserção AluyHG ». Universidade Federal de Goiás, 2013. http://repositorio.bc.ufg.br/tede/handle/tede/6686.
Texte intégralApproved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2017-01-04T13:01:13Z (GMT) No. of bitstreams: 2 Dissertação - Kaisson Ernane dos Santos - 2013.pdf: 2738475 bytes, checksum: 6c79ab9177dd126fa5cb677127debc2c (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)
Made available in DSpace on 2017-01-04T13:01:13Z (GMT). No. of bitstreams: 2 Dissertação - Kaisson Ernane dos Santos - 2013.pdf: 2738475 bytes, checksum: 6c79ab9177dd126fa5cb677127debc2c (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2013-11-25
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES
The Major Histocompatibility Complex is mainly composed by genes of the adaptive immune response. In humans, part of this complex is known as the Human Leukocyte Antigens (HLA), whose genes are responsible for specific antigen presentation to effector immune cells. The classical class I HLA genes (HLA-A, -B and -C) are responsible for antigen presentation to T CD8+ cells and they constitute the most polymorphic genes in the human genome. This variability is maintained by selection mediated by microorganisms. In contrast to their classical counterparts, the non classical class I genes (HLA-G, -E and -F) present low variability and are associated with immune tolerance due to the interaction with NK and T cells inhibitor receptors. HLA-G is the most studied non classical gene, which is associated with immune response modulation, mainly during pregnancy. Considering that natural selection is acting on the HLA-G regulatory regions maintaining high heterozigosity in this region, we evaluated a nearby Alu insertion (AluyHG) correlating this Alu element with coding and 3’UTR HLA-G polymorphisms. The AluyHG insertion was particularly associated with the HLA-G haplotype known as G*01:01:01:01/UTR-1, considered a high-expressing HLA-G haplotype. The G*01:01:01:01/UTR-1/AluyHG haplotype would be the most recent HLA-G haplotypes, in spite of its high frequency in worldwide populations.
O Complexo Principal de Histocompatibilidade (MHC) é formado principalmente por genes que participam da resposta imunológica adaptativa. Entre esses genes encontramos o grupo denominado de Antígenos Leucocitários Humanos (HLA), que são responsáveis pela apresentação de antígenos específicos às células efetoras do sistema imunológico. Os genes HLA de classe I clássicos (HLA-A, -B e -C), responsáveis pela apresentação antigênica aos linfócitos T citotóxicos, são considerado como os mais polimórficos do genoma humano e de outros vertebrados. A variabilidade desses genes e elevada heterozigose é mantida por seleção mediada por microrganismos. Diferentemente dos genes clássicos, os genes HLA de classe I não clássicos (HLA-G, -E e -F) apresentam variabilidade reduzida e como função principal a tolerância imunológica, por meio de sua interação com receptores inibitórios presentes nas células NK e T. O HLA-G é o mais estudado entre esses genes e, devido sua importância como molécula imunomoduladora e sua importância em situações como gestação, e considerando evidências anteriores de seleção natural mantendo uma elevada heterozigose nas regiões regulatórias do HLA-G, avaliamos a presença de uma inserção Alu (AluyHG) próxima a este gene correlacionando os achados com a variabilidade contida nas suas regiões codificadora e 3’ não traduzida. A inserção AluyHG mostrou-se em desequilíbrio de ligação (LD) com os polimorfismos do gene HLA-G. Especificamente, o elemento inserido apresentou-se em LD com um haplótipo denominado G*01:01:01:01/UTR-1, considerado como um haplótipo de alta produção da molécula de HLA-G. Esse haplótipo aparentemente é o mais jovem entre humanos, apesar de sua elevada frequência nas populações estudadas até o momento.
Sheshgiri, Rohit. « The Role of Human Leukocyte Antigen-G in Heart Transplantation ». Thesis, 2008. http://hdl.handle.net/1807/17223.
Texte intégralChapitres de livres sur le sujet "Human Leukocyte Antigen-G"
Hviid, Thomas Vauvert F. « Human Leukocyte Antigen-G Within the Male Reproductive System : Implications for Reproduction ». Dans Advances in Experimental Medicine and Biology, 171–90. Cham : Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-18881-2_8.
Texte intégral« Assessment of soluble human leukocyte antigen G in human embryos ». Dans Human Preimplantation Embryo Selection, 159–68. CRC Press, 2007. http://dx.doi.org/10.3109/9780203089712-16.
Texte intégralFisch, Jeffrey D., Levent Keskintepe et Geoffrey Sher. « Assessment of soluble human leukocyte antigen G in human embryos ». Dans Human Preimplantation Embryo Selection, 145–54. Informa Healthcare, 2007. http://dx.doi.org/10.3109/9780203089712.012.
Texte intégralChimote, Natachandra. « Chapter-28 Soluble Human Leukocyte Antigen-G : Embryology in the Era of Proteomics ». Dans Manual of Cytogenetics in Reproductive Biology, 230–37. Jaypee Brothers Medical Publishers (P) Ltd, 2014. http://dx.doi.org/10.5005/jp/books/12003_28.
Texte intégralActes de conférences sur le sujet "Human Leukocyte Antigen-G"
Elliott, Robert L., Xian P. Jiang, Jeffery T. Phillips et Jonathan F. Head. « Abstract 5409 : Cancer immunosuppression : The role of human leukocyte antigen G expression ». Dans Proceedings : AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012 ; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-5409.
Texte intégralBoujelbene, N., I. Zemni, W. Babay, H. Ben Yahia, S. Dhouioui, K. Mrad, HI Ouzari, L. Charfi et I. Zidi. « EPV285/#322 Human leukocyte antigen-g expression in vulvar squamous cell carcinoma ». Dans IGCS 2021 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/ijgc-2021-igcs.356.
Texte intégralAbbas, Ata, Syed R. Hussain, Hena Naqvi, Rabab Fatima, Sikandar Hasan et Farzana Mahdi. « Abstract 1488 : Role of human leukocyte antigen-G (HLA-G) in cancer progression and susceptibility ». Dans Proceedings : AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010 ; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-1488.
Texte intégralWhite, SR, J. McConville, D. Loisel, YL Tu, R. Stern, BA Marroquin et C. Ober. « Expression of Human Leukocyte Antigen-G in Airway Epithelium and Bronchoalveolar Lavage of Normal and Asthmatic Subjects. » Dans American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a3924.
Texte intégralJan, Chia-Ing, Shi-Wei Huang, Peter Canoll, Yu-Chuan Lin, Hsin-Man Lu, Shao-Chih Chio et Der-Yang Cho. « Abstract A61 : Human leukocyte antigen G as a novel target for switch-based chimeric antigen receptor natural killer cell therapy of solid cancers ». Dans Abstracts : AACR Special Conference on Tumor Immunology and Immunotherapy ; November 17-20, 2019 ; Boston, MA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/2326-6074.tumimm19-a61.
Texte intégral